Smartphone app and fitbit join forces to monitor lung cancer treatment side effects
NCT ID NCT05370469
First seen Jan 11, 2026 · Last updated May 04, 2026 · Updated 18 times
Summary
This study involves 30 adults with lung cancer who are taking oral targeted therapy (TKIs). Participants use a smartphone app, a Fitbit, and a smart pill cap for up to 24 weeks to track symptoms and medication use. The goal is to see if this remote system is practical and to guide future tools that improve quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Virginia
Charlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.